Adar Poonawalla, CEO of Serum Institute of India (SII), announced on Wednesday that production of the COVID-19 vaccine Covishield has resumed in response to an increase in the number of cases of the viral infection. He stated that adults must receive the booster dose of the Covovax vaccine, which the business already has six million doses of accessible.
In response to claims of a shortage of COVID-19 vaccines, he indicated that although manufacturers are prepared, there hasn't been any demand.
Poonawalla told PTI "Just as a precaution, at risk, we have done it so that people have a Covishield as a choice if they want it," on restarting manufacturing of the vaccine. In December 2021, the company stopped producing Covishield.
He stated regarding Covovax that "We have six million doses ready but the demand is exactly zero." Covovax has been licensed as a booster dosage for patients 18 years of age and older.
© Copyright 2023. All Rights Reserved Powered by Vygr Media.
